Softwr

Healthcare · head to head

Fujifilm Synapse vs PathAI

Fujifilm Synapse logo

Fujifilm Synapse

Healthcare

Enterprise imaging platform covering PACS, VNA, cardiology and 3D from Fujifilm Healthcare

From
On request
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Fujifilm Synapse pACS, VNA, Cardiovascular and 3D are separately licensed and separately versioned, so an enterprise deployment means four upgrade cycles and four support relationships under one brand rather than one platform upgrade.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Fujifilm Synapse covers Synapse PACS, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Fujifilm Synapse and PathAI actually diverge.

Attributes where Fujifilm Synapse and PathAI differ
AttributeFujifilm SynapsePathAI
PlatformsWeb, Windows, iOS, AndroidWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Fujifilm Synapse

  • Synapse PACS
  • Synapse VNA
  • Synapse Cardiovascular
  • Synapse 3D
  • Synapse Mobility
  • Deconstructed PACS support
  • Cloud services

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Fujifilm Synapse

  • A hospital replacing PACS that wants the archive decoupled from its scanner vendor so future modality purchases stay competitivenot PathAI
  • A health system consolidating radiology, cardiology, ophthalmology and wound images into one vendor neutral archive with a single retention policynot PathAI
  • An outpatient imaging chain that needs one worklist across multiple sites and radiologists reading remotelynot PathAI
  • A site pursuing a deconstructed PACS strategy that wants to replace the viewer later without touching the archivenot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Fujifilm Synapse
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Fujifilm Synapse
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Fujifilm Synapse
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Fujifilm Synapse

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Fujifilm Synapse

  • PACS, VNA, Cardiovascular and 3D are separately licensed and separately versioned, so an enterprise deployment means four upgrade cycles and four support relationships under one brand rather than one platform upgrade.
  • Synapse 3D is licensed by concurrent user and sized from average concurrency, which leaves radiologists queued for advanced visualisation at the morning reading peak and forces an unplanned licence purchase.
  • As an independent informatics vendor Fujifilm has less privileged access to proprietary modality data than Philips or Siemens have on their own scanners, so some vendor specific post processing is not available.
  • The vendor neutral archive absorbs non DICOM object types only after per specialty configuration work, and departments such as ophthalmology and dermatology usually need bespoke ingestion projects that were not in the original scope.
  • Migrating a decade of priors from a legacy archive is a large professional services line that Fujifilm quotes separately, and these migrations regularly run past the contracted go live date.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Fujifilm Synapse

On request
  • Synapse$undefined/year
    • Each module licensed separately: PACS, VNA, Cardiovascular, 3D
    • Priced by annual study volume and concurrent diagnostic users
    • Synapse 3D licensed by concurrent user, separate from PACS

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Fujifilm Synapse if

  • You need synapse pacs.
  • You work on Web, Windows, iOS, Android.
  • You also want synapse vna.
Fujifilm Synapse review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Fujifilm Synapse or PathAI better?
Neither clearly leads. Fujifilm Synapse starts at On request and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Fujifilm Synapse or PathAI?
Fujifilm Synapse starts at On request and PathAI at On request.
Does Fujifilm Synapse or PathAI run on more platforms?
Fujifilm Synapse runs on Web, Windows, iOS, Android. PathAI runs on Web.
What is Fujifilm Synapse best used for?
Fujifilm Synapse is most often used for a hospital replacing pacs that wants the archive decoupled from its scanner vendor so future modality purchases stay competitive, a health system consolidating radiology, cardiology, ophthalmology and wound images into one vendor neutral archive with a single retention policy, an outpatient imaging chain that needs one worklist across multiple sites and radiologists reading remotely, a site pursuing a deconstructed pacs strategy that wants to replace the viewer later without touching the archive. Of those, a hospital replacing pacs that wants the archive decoupled from its scanner vendor so future modality purchases stay competitive and a health system consolidating radiology, cardiology, ophthalmology and wound images into one vendor neutral archive with a single retention policy are not what PathAI is typically brought in for.
What can Fujifilm Synapse do that PathAI cannot?
Fujifilm Synapse covers Synapse PACS, Synapse VNA, Synapse Cardiovascular, Synapse 3D. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Fujifilm Synapse: Is Synapse one product or several?

Several. Synapse PACS, Synapse VNA, Synapse Cardiovascular and Synapse 3D are separately licensed products under one brand. Price and scope each one individually.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Fujifilm Synapse: Do I have to buy Fujifilm scanners?

No. Fujifilm sells Synapse independently of imaging hardware, which is a large part of why it wins competitive PACS replacements at mixed fleet sites.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Fujifilm Synapse: Does Synapse publish pricing?

No. Pricing is quoted by study volume, concurrent users, module mix and storage capacity.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Fujifilm Synapse: Can Synapse VNA store non radiology images?

Yes, including visible light, ophthalmology and wound photography, but each specialty typically needs its own ingestion and metadata configuration project.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Fujifilm Synapse

More on PathAI

Keep looking

Other head to heads